ArticlePharmacology research & perspectives2024

Preclinical metabolism and the disposition of vornorexant/TS-142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia.

Yoshihiro Konno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.